James William Rogers Sells 22,529 Shares of Tempus AI (NASDAQ:TEM) Stock

Key Points

• Tempus AI CFO James William Rogers sold 22,529 shares at an average price of $49.61, worth approximately $1.12 million. The Rule 10b5-1 transaction was intended to cover tax obligations tied to vested equity awards, reducing his holdings by 14.55%.
• Tempus AI shares rose 8.8% to $66.65 amid strong trading volume. The company recently beat quarterly EPS and revenue estimates, with revenue increasing 21.6% year over year, though it remains unprofitable.
• Analyst sentiment is mixed, with nine Buy, six Hold, and two Sell ratings and a consensus price target of $65.69. Positive attention centers on BTIG’s $80 price target and Tempus AI’s proposed approximately $1.5 billion acquisition of Personalis.

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CFO James William Rogers sold 22,529 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total value of $1,117,663.69. Following the sale, the chief financial officer owned 132,337 shares of the company's stock, valued at approximately $6,565,238.57. This represents a 14.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

James William Rogers also recently made the following trade(s):

• On Wednesday, August 19th, James William Rogers sold 26,313 shares of Tempus AI stock. The shares were sold at an average price of $60.00, for a total value of $1,578,780.00.
• On Thursday, June 25th, James William Rogers sold 11,529 shares of Tempus AI stock. The stock was sold at an average price of $55.00, for a total value of $634,095.00.

Tempus AI Stock Up 8.8%

Shares of Tempus AI stock traded up $5.40 during trading on Thursday, hitting $66.65. 20,103,049 shares of the stock traded hands, compared to its average volume of 5,600,288. The company has a fifty day moving average price of $52.44 and a two-hundred day moving average price of $51.21. Tempus AI, Inc. has a twelve month low of $40.77 and a twelve month high of $104.32. The stock has a market cap of $12.03 billion, a P/E ratio of -46.28 and a beta of 3.58. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30.

Tempus AI (NASDAQ:TEM - Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The firm had revenue of $382.49 million during the quarter, compared to analysts' expectations of $379.69 million. During the same period in the previous year, the company earned ($0.22) earnings per share. The company's revenue was up 21.6% compared to the same quarter last year. Equities research analysts predict that Tempus AI, Inc. will post -1.38 EPS for the current fiscal year.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target to $80 from $70 and maintained a “Buy” rating, implying roughly 20% upside from the referenced price. The upgrade provided a direct catalyst for investor buying. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is focusing on Tempus AI’s approximately $1.5 billion stock-based agreement to acquire Personalis. The deal is increasingly viewed as strategically valuable because Personalis’ genomic data and cancer-testing capabilities could strengthen Tempus’ precision-medicine and drug-development platform. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Moderna’s reported cancer-vaccine progress, alongside developments involving Merck, has encouraged investors to believe Tempus’ Personalis acquisition could benefit from increased demand for genomic data and personalized cancer treatment. The connection is indirect, but it has improved sentiment around Tempus’ strategic positioning. Tempus AI stock rises after Merck-Moderna cancer vaccine breakthrough
• Positive Sentiment: The rally was accompanied by unusually high options activity, with investors buying 40,671 call contracts—about 57% above average daily call volume—signaling increased bullish speculation and potentially reinforcing upward momentum.
• Neutral Sentiment: Technical factors also contributed: TEM moved above key moving averages, while coverage characterized the move as a possible short squeeze. These conditions can accelerate gains but may also increase volatility. Tempus AI stock technical rally

Institutional Investors Weigh In On Tempus AI

Several hedge funds have recently made changes to their positions in the stock. Headlands Technologies LLC acquired a new stake in Tempus AI during the second quarter worth about $2,689,000. Public Employees Retirement System of Ohio bought a new position in Tempus AI during the second quarter valued at about $1,775,000. Monetta Financial Services Inc. acquired a new position in Tempus AI in the 2nd quarter valued at approximately $1,159,000. Handelsbanken Fonder AB raised its holdings in Tempus AI by 4.1% in the 2nd quarter. Handelsbanken Fonder AB now owns 32,900 shares of the company's stock valued at $1,906,000 after acquiring an additional 1,300 shares in the last quarter. Finally, CoreCap Advisors LLC raised its holdings in Tempus AI by 293.4% in the 2nd quarter. CoreCap Advisors LLC now owns 1,019 shares of the company's stock valued at $59,000 after acquiring an additional 760 shares in the last quarter. Institutional investors own 24.22% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on TEM. Lake Street Capital downgraded Tempus AI to a "hold" rating in a report on Monday, July 20th. Piper Sandler decreased their price objective on shares of Tempus AI from $58.00 to $56.00 and set a "neutral" rating for the company in a report on Tuesday, August 4th. Wolfe Research started coverage on shares of Tempus AI in a research note on Tuesday, June 2nd. They issued a "peer perform" rating on the stock. Weiss Ratings upgraded shares of Tempus AI from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, August 12th. Finally, Needham & Company LLC reissued a "buy" rating and set a $75.00 target price on shares of Tempus AI in a research report on Friday, July 31st. Nine analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $65.69.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source